Dosing and monitoring of low-molecular-weight heparins in special populations.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewEnoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiencyEnoxaparin in acute coronary syndromesImplementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma.Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.Minimising the risk of heparin-induced osteoporosis during pregnancy.Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsA comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.Therapeutic equivalency of low-molecular-weight heparins.Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.Monitoring of low molecular weight heparin in pregnancy.Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Tinzaparin: considerations for use in clinical practice.Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.Clinical approach to the critically ill, morbidly obese patient.Anticoagulation in pregnant women with prosthetic heart valves.Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.Clinical and critical care concerns in severely ill obese patient.Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.Medication-related complications in the trauma patient.Primary prophylaxis of venous thromboembolism in surgical patients.Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.Update on pharmacologic therapy for pulmonary embolism.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.Association of outcomes and anti-Xa levels in the treatment of pediatric venous thromboembolism.Dosing of Enoxaparin in Renal Impairment.Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls.Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy.Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function.The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study.Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight.Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery.Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
P2860
Q26992262-5E81B571-395A-41A9-8753-971C68883DB0Q28175651-329C7CA9-7B26-4F39-9F71-453D21538301Q28301431-0B4C3666-5805-4390-BE16-DDA5A4EBBDBFQ33337707-49CB0260-D6CD-4803-B5F1-8BBD17FFD2CEQ33365781-BEBBD0F6-9199-44D5-B63F-8DCB5ED1B3B8Q33366632-E605A8BF-C0B7-4E92-A054-2E5986AE7BD2Q33383622-EE8FDA1A-3128-4C12-B383-6AECBAF119ADQ33754841-04B7768D-AA77-48E0-BA86-19B0633515BCQ33919099-0C8D3015-F29C-4FB6-8545-A6EC36026EE3Q34648639-F7D086A2-0276-4B20-B848-458DDBFBF20AQ34999668-BED1D47C-F952-4707-9801-4B559251A557Q35080331-92B905C9-A799-4345-B1FB-988F07EF49B5Q35368813-17693C94-8EA5-4A68-97CB-E54741B41443Q35591002-1AA2BDD9-F35C-4030-9000-9D56822ADC3CQ35624232-32B788D6-0837-4001-A6E2-4A620F8217FBQ35675079-89A9EE49-3CB6-43A8-A66F-C51B8C41BF99Q35862159-2C4261C9-0AB8-4C53-8FF5-298BE2BB1FC0Q36022983-EF7B5DBB-9579-412A-AA52-2B3E4B7D76D4Q36331619-1EFC312E-FFC3-4767-8B4E-F5DB91CB4F41Q36603232-8F230B12-7891-41D1-9330-E5F8BB7AF1C6Q37121344-AA90F06F-7DE1-4611-B11F-E9E660C3E741Q37122818-1F949973-1456-4767-A83A-2BD9E2C7D6F5Q37302477-0402DD17-D05D-4103-AD23-98636AC511ACQ37490581-036D7899-4735-45D4-8780-054C6A290FD5Q38000240-437FD664-D1EA-4180-98A1-020DFE7CDBD0Q38157555-4E152CE9-B542-46C8-9068-50854D56BB5FQ38168477-A3BCF0E9-15F9-4A7E-92F2-05A1803C98A1Q38776899-8B443F1D-3402-4097-B4A7-34E63ED873A8Q38851458-A7DE3324-9871-4094-A155-75469D8D115AQ40284785-9AFA1AF8-2A0C-4453-9B08-B9DAA9D7D92DQ42658234-5A4A0D1F-6A36-48EB-8944-5BAEF18D18DCQ43805858-5EC67463-6FBF-42F7-9675-ED024EF1C52BQ45029803-18FFCA99-CC52-42C1-AB76-5670FE62D3DDQ45045888-1941529F-244B-41A4-9CE9-9FE9CD1B107DQ46520643-08F79018-26FA-4932-B8D2-E29960E1110EQ46831995-7B4A862C-3ABC-4DF3-A84C-A1AF65EF2443Q47328313-EBB64BCE-1B4C-422F-8CC1-C131E58EC269Q47353736-78280ACB-3456-45EA-A557-A271732E4402Q47432203-9BF6D3DB-FB13-4E25-8EAD-313E940F2329Q50085838-FBAD54D6-6AE3-402D-9509-BA1588C2634D
P2860
Dosing and monitoring of low-molecular-weight heparins in special populations.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dosing and monitoring of low-molecular-weight heparins in special populations.
@ast
Dosing and monitoring of low-molecular-weight heparins in special populations.
@en
type
label
Dosing and monitoring of low-molecular-weight heparins in special populations.
@ast
Dosing and monitoring of low-molecular-weight heparins in special populations.
@en
prefLabel
Dosing and monitoring of low-molecular-weight heparins in special populations.
@ast
Dosing and monitoring of low-molecular-weight heparins in special populations.
@en
P2093
P2860
P1433
P1476
Dosing and monitoring of low-molecular-weight heparins in special populations.
@en
P2093
P2860
P304
P356
10.1592/PHCO.21.2.218.34112
P407
P577
2001-02-01T00:00:00Z